TransCelerate selects Cognizant as development partner for clinical trials system
Built as an industry utility, the technology will help speed up development of new medicines
Cognizant, a multinational IT business, will develop a subscription-based platform for TransCelerate BioPharma to help pharmaceutical companies transform the way clinical sites collaborate on clinical trials.
TransCelerate BioPharma is a non-profit organisation representing 19 major pharma companies dedicated to making the R&D process more efficient across the pharmaceutical industry.
The Shared Investigator Platform, which will be built as an industry utility, will enable the pharma industry to bring standardisation and consistency to clinical trials, said Cognizant.
Bringing together clinical sites and sponsors across the world on a common platform will enable pharmaceutical companies to run clinical trials more efficiently and accelerate the development of new medicines, the company added.
The new platform will improve organisational efficiency by providing investigators and site staff with a central, single access point to clinical trial information, enhancing accuracy, and reducing study start-up time.
It will also help pharmaceutical companies to improve quality, regulatory compliance, process visibility and capacity.
In the future, the platform may also provide regulators with an efficient electronic audit process and better insight into clinical trials.
'The Shared Investigator Platform will benefit sites by simplifying processes, and reducing time and effort spent on standard study activities,' said Jackie Kent, Shared Investigator Platform Leader, TransCelerate.
Bhaskar Sambasivan, Vice President of Cognizant's Life Sciences practice, added: 'Streamlining the clinical trials process will enable TransCelerate's member companies not only to speed up drug development, but also drive innovation in improving patient health. We are making a significant commitment and investment in this strategic relationship.'
